A股異動丨思創醫惠漲停 中國將制定智慧醫療行業標準
格隆匯10月25日丨思創醫惠(300078.SZ)漲停,報13.88元,總市值112億元。中國衞生信息與健康醫療大數據學會日前成立智慧醫院與人工智能應用專業委員會、標準委員會和工作委員會,未來將制定中國智慧醫療與人工智能應用的行業標準。專業委員會抓住前沿的、方向性的、根本性的事情,大力推動創新、研發,凝聚全行業及相關行業的力量,推動事業、產業的融合發展;標準委員會以標準制定為主要工作,儘快將相關標準提交給國家標委會,以成為行業標準;工作委員會團結所有相關單位、個人,做好和推動智慧醫院和人工智能應用。此前,公司收購醫惠科技後發力智慧醫療。今年5月份,醫惠科技承擔的“基於知識圖譜的醫學人工智能示範應用”項目獲批立項。此外,醫惠科技與浙江大學醫學院附屬第一醫院等共同完成的“基於人工智能技術的數字化醫院建設及應用推廣”項目,榮獲2018年度浙江省科學技術進步獎二等獎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.